GlassScriptPhysician profile
Neena James
NPI 1952753659
$73,655.36
in general payments reported to CMS, 2019-2025
22 companies · $4,075 in 2025
The $4,075 reported for 2025 was more than what 99% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,994 · 2020: $2,934 · 2021: $22K · 2022: $29K · 2023: $3,945 · 2024: $9,402 · 2025: $4,075.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,369 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $5,299 · Consulting Fee: $2,950 · Travel and Lodging: $2,663 · Long Term Medical Supply Or Device Loan: $140.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,369.08 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $5,299.45 |
| Consulting Fee | $2,950.00 |
| Travel and Lodging | $2,663.28 |
| Long Term Medical Supply Or Device Loan | $140.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $44,498.83 | 2019-2022 | |
| Abbvie INC. | $22,356.58 | 2022-2025 | |
| Lumenis Be INC | $2,300.00 | 2025 | Optilight |
| Sun Pharmaceutical Industries INC. | $683.54 | 2020-2025 | Cequa, Xelpros |
| Alcon Vision LLC | $526.59 | 2019-2025 | Precision7, Precision 1, Tryptyr |
| Johnson & Johnson Vision Care, INC. | $507.32 | 2020-2024 | Acuvue |
| Oyster Point Pharma, INC. | $371.51 | 2023-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $332.70 | 2019-2021 | |
| Biotissue Holdings INC. | $308.81 | 2023-2025 | |
| Glaukos Corporation | $251.99 | 2023-2024 | Idose |
| Novartis Pharmaceuticals Corporation | $236.88 | 2019-2023 | |
| Tarsus Pharmaceuticals, INC. | $224.51 | 2024-2025 | Xdemvy |
| Astellas Pharma US INC | $177.07 | 2023-2025 | Izervay |
| Coopervision INC. | $176.41 | 2020-2025 | Misight Contact Lens, Clariti Contact Lens |
| Ocular Therapeutix, INC. | $156.22 | 2024 | Dextenza |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harrow Eye, LLC | $147.15 | 2025 | Vevye |
| Bausch & Lomb Americas INC. | $126.37 | 2022-2025 | Xiidra, Miebo, Vyzulta |
| Horizon Therapeutics Plc | $109.99 | 2023 | Tepezza |
| Dompe US, INC. | $78.68 | 2022-2025 | Oxervate |
| Shire North American Group INC | $40.24 | 2019 | |
| Genentech USA, INC. | $23.44 | 2023 | Vabysmo |
| Thea Pharma INC. | $20.53 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Neena James listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.